Topics Presented this February 2018 at RNA Therapeutics
Want to learn about exploiting exosomes for therapeutic use in patients with cystic fibrosis?
Have questions answered during our two sessions presented by ProQR Therapeutics and University of Oxford.
Exploiting Exosomes for Therapeutic and Diagnostic Applications | Day 2 | @16:40
This presentation will examine the translational applications of exosome research, including biomarker discovery and drug delivery. The session will consider and evaluate of the important advantages compared to other nanoparticulate drug delivery systems and look at ways of overcoming potential problems with component characterization and immune reactions.
Presented by: Samir EL Andaloussi, Assistant Professor, Karolinska Institutet and Research Fellow, University of Oxford
RNA Therapeutics for Patients with Cystic Fibrosis: QR-010 and Beyond | Day 1 | @11:00
This session will explore the opportunities that RNA therapeutics may bring for patients with cystic fibrosis. The evidence for QR-010 as a meaningful RNA therapeutic for patients with cystic fibrosis will be discussed, looking specifically at the F508del mutation. Other mutations will also be explored while looking at RNA therapeutic approaches for patients with cystic fibrosis.
Presented by: Noreen Roth Henig, Chief Medical Officer, ProQR Therapeutics
- Hear from MiNA Therapeutics about their new pre-clinical data supporting the on-target mechanism of action of their pioneering new drug candidate MTL-CEBPA.
- Learn how CureVac’s sophisticated technologies and approaches have helped overcome limitations such as the instability of single-stranded RNA.
- Discover STORM Therapeutics’ innovative approach: Harnessing the power of RNA epigenetics to develop first-inclass drugs in oncology.
- Expand knowledge of patenting RNA Therapeutics, with James Ogle, a European and UK Chartered Patent Attorney with particular expertise in RNA and other nucleic acidbased technologies.
- Examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches.
For those looking to attend there is currently a £200 early-bird saving, ending November 30th.
Further information is available at: www.therapeutics-rna.com/opr
SMi presents the 9th Annual Conference:
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Sponsored by: ChemGenes | Phion Therapeutics
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: email@example.com
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Westminster Bridge Road
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Topics Presented this February 2018 at RNA Therapeutics here
News-ID: 824116 • Views: 380
More Releases from SMi Group
Exclusive interview from HK Packaging Consulting speaker released for SMi’s Pr …
SMi Reports: HK Packaging Consulting GmbH to present at Pre-Filled Syringes and Injectable Drug Devices conference 2020, this January. The Pre-Filled Syringes and Injectable Drug Devices conference will return on 15th- 16th January 2020 in London for its 12th year. This event is Europe’s leading PFS conference which will explore topics such as: advancements in design controls and applications for injectable products, enhancement of the user interface and human factors, and
Dr Samareh Lajaunias, Director at Combioxin Speaking at SMi's 22nd Annual Superb …
The 22nd Annual Superbugs & Superdrugs Conference will convene on 30th and 31st March 2020 in London. The conference will concentrate on novel drugs and approaches, highlighting non-traditional and traditional therapies that provide an innovative means to tackle the continued rise of antibiotic resistance, while placing significant emphasis on the much-needed support for these innovations. Ahead of the event, SMi caught up with Combioxin SA’s Director, Dr. Samareh Azeredo da
Invite from Lynne Ensor chair for Pharma Microbiology East Coast Conference, Apr …
SMi’s 3rd Annual Pharmaceutical Microbiology East Coast Conference is scheduled to take place the April 29th – 30th, 2020 in Boston. Attendees can expect a wide array of microbiology expert speakers from leading pharmaceutical companies to meet and collaborate on all aspects of Pharmaceutical Microbiology. With advances in rapid microbiological methods, constant regulatory updates, enhanced knowledge of innovation therapeutics, and novel testing methods, this industry is ever expanding. This year’s conference
Pre-Filled Syringes East Coast 2020 to Discuss Key Topics Driving the Industry
Building on the success of last year’s event, which saw 100+ attendees convene in Boston, Pre-Filled Syringes East Coast will bring together industry leaders to discuss regulations, new digital technology trends, human studies and innovative design and delivery systems in the pre-filled syringe industry. The conference, which will be held in Boston on the 27th and 28th of April 2020, will explore industry challenges and the changing global market,
More Releases for RNA
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
RNA Sequencing: Technologies and Analyses of Global Market Trends
"The Latest Research Report RNA Sequencing: Technologies and Global Markets provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The global RNA-Sequencing market reached nearly $1.1 billion in 2015, and should reach $1.2 billion in 2016 and $2.1 billion in 2020, registering a compound annual growth rate (CAGR) of 14.9%. The tools and reagents segment should reach over $1.0 billion in 2020 from $566.8
RNA Analysis Market worth 3.62 billion USD by 2021
RNA Analysis Market size was around USD 1.89 billion in 2016. It is expected to grow at a CAGR of 13.9% to reach USD 3.62 billion by 2021. The market is mainly driven by the increasing technological advancements, increasing investment in research and development by biotechnology and pharmaceutical companies, rising government and private funding, and growing preference for personalized medicines. However, lack of skilled professionals in the transcriptomics field and lack
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and